Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Recent progressions in women’s health, non-invasive methods, and the need for effective treatment alternatives are the primary ideologies behind key trends in the Uterine Fibroid Treatment Device Market. As a result, there has been an increased demand for novel devices that can be utilized to treat this illness. Noting that over the years, several important factors have defined the Uterine Fibroid Treatment Device Market including patient-focused approach, technology innovation and move from traditional surgical interventions.
A major trend that is emerging in the Uterine Fibroid Treatment Device Market is the growing uptake of minimally invasive techniques for fibroid treatment. Some of these procedures include laparoscopic or hysteroscopic surgeries and non-surgical treatments such as uterine artery embolization (UAE) and focused ultrasound therapy. In line with general healthcare trends towards less invasive techniques with shorter recovery periods, these techniques offer reduced hospital stays, lower complications rates and higher satisfaction levels among patients compared to traditional open surgery.
Technological advances in fibroid treatment devices are also spurring innovation within the market. Advanced imaging technologies such as magnetic resonance imaging (MRI) guidance for focused ultrasound therapy improve precision and accuracy of treating fibroids while new radiofrequency ablation (RFA) and microwave ablation technologies add more choices to enable medical professionals effectively targeting and shrinking uterine fibroids. Application of advanced technologies sets stage for numerous shots at curing diseases with respect to individual needs thereby expanding on options when it comes to curative measures.
Additionally, there is a shift towards outpatient-based practices in managing fibroids using specialized devices within this market segment. Outpatient-based surgery offers high accessibility due to decreased time spent by patients at hospitals among other advantages associated with fewer infections which results from use of sterile operating environments. Consequently, many women can go home soon after undergoing their treatments or avoid hospital admissions completely thus giving them a chance to recuperate quickly and get back to their daily lives. This is in line with growing emphasis on patient-centered care and increased access to healthcare.
Similarly, there is a growing preference for uterine-preserving treatment options within the market. In light of this development, women with fibroids are increasingly concerned about preserving fertility and focus mainly on treatment techniques that can facilitate this while at the same time keeping the womb open for possible future pregnancies. Some minimally invasive procedures such as hysteroscopic myomectomy and fertility-sparing fibroid embolization cater to such individuals’ demands thereby indicating how individualized care is important within the Uterine Fibroid Treatment Device Market.
In addition, there has been a move towards increasing patient awareness in the Uterine Fibroid Treatment Device Market. As more women learn about uterine fibroids and available treatment options, they want to be involved in decision making concerning their health. Early detection through heightened awareness leads to timely treatment hence better outcomes. Patient education therefore falls into place as an effort by healthcare providers to allow people manage their health issues and choose wisely on what they need done.
Medical device manufacturers, health care institutions as well as research organizations are the forces behind research and development efforts in Uterine Fibroid Treatment Device Market. These partnerships enable knowledge exchange, clinical insights, and technology expertise that led to invention of new treatment devices and methods. The cooperation between industry players and medical practitioners is promoting innovations in fibroid treatments hence promising better patient outcomes.
Despite these positive trends, a number of challenges remain in the Uterine Fibroid Treatment Device Market such as long-term efficacy data requirements, insurance coverage concerns, and disparities in access to advanced treatments. Longitudinal studies to determine emerging therapies’ effectiveness; improved insurance coverage advocacy; and awareness-raising campaigns to extend the scope of patients are some of strategies used toward these ends.
Uterine Fibroid Treatment Device Market Highlights:
Global Uterine Fibroid Treatment Device Market Overview
Uterine Fibroid Treatment Device Market Size was valued at USD 5.2 Billion in 2022. The Uterine Fibroid Treatment Device market industry is projected to grow from USD 5.73 Billion in 2023 to USD 12.46 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.20% during the forecast period (2023 - 2032).The main market driver fueling market expansion is the high frequency of uterine fibroids among women. 
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Uterine Fibroid Treatment Device Market Trends
-
Rising incidence of uterine fibroids is driving the market growth
One of the main factors boosting the market revenue growth is the increasing prevalence of uterine fibroids. According to the National Institutes of Health (NIH), 70% of white women and 80% of African American women in the United States, respectively, will have uterine fibroids by the time they are 50. The high prevalence of the condition is driving the demand for state-of-the-art uterine fibroids therapy equipment, such as Magnetic Resonance Imaging (MRI)-guided Focused Ultrasound (MRgFUS) and Radiofrequency Ablation (RFA) devices. These devices offer a non-invasive or slightly invasive substitute for popular surgical treatments including hysterectomy and myomectomy.
Additionally, an increase in patients' preferences for minimally invasive and non-invasive fibroids operations is anticipated to boost market expansion. Smaller incisions reduce post-operative pain and speed up recovery, which encourages widespread use of these procedures. A number of significant firms are investing in R&D to bring cutting-edge minimally invasive surgical devices to market. One of the incisionless techniques that is highly suggested by doctors is the MR-guided Focused Ultrasound (MRgFUS) used to treat uterine fibroids.
Targeted tissue from the uterine cavity is heated and removed during this treatment by the device's ultrasonic beams. Since this is a non-invasive procedure, there are little to no side effects, and patients can resume their regular activities in a few days. Thus, it is projected that the market for uterine fibroids treatment devices would increase due to the increased demand for such operations due to their minimum pain, effectiveness, reduced risk of infection, and quick recovery as compared to open surgeries.
Various governments and commercial groups are launching a number of campaigns to raise awareness about early fibroids detection and treatment. For instance, July is "Fibroids Awareness Month" in the United States. Uterine fibroids have been the subject of expanded awareness campaigns in recent years. The White Dress Project, HealthyWomen.org, Fibroids Project, and Center for Innovative GYN Care are a few of the noteworthy initiatives.
In order to spread awareness about fibroids, The White Dress Project organization educates women about the essentials while also raising money for research. Women are encouraged to join and participate in this project and to share their stories. The Fibroids Project is a website and community dedicated to assisting women in eradicating their fibroids. Their goal is to arm medical professionals and women with complete knowledge about recent research, initiatives, and practices. The market growth is projected to be boosted by women's rising knowledge of uterine fibroids, their treatment, and activities.
Uterine Fibroid Treatment Device Market Segment Insights
Uterine Fibroid Treatment Device Technology Insights
The Uterine Fibroid Treatment Device Market segmentation, based on Technology includes Surgical Techniques, Laparoscopic Techniques, Ablation Techniques, and Embolization Techniques. The surgical techniques segment dominated the overall market with a share of 33.9% in 2022. The most common surgical procedures for treating fibroids in women are hysterectomy and myomectomy, which account for the rise in their number. Additionally, this method is the most popular and effective long-term cure for uterine fibroids. Thus, a rise in associated surgeries is anticipated to support segment expansion.
The ablation methods market is anticipated to grow at the highest CAGR of 10.2%. The uterine endometrial lining is surgically removed using this least invasive method. This surgical procedure is frequently used to treat severe menstrual bleeding. Endometrial ablation does not require incisions and can be performed at the doctor's office without requiring general anesthesia. In addition, pregnancy is feasible following endometrial ablation. Benefits provided by ablation procedures are therefore anticipated to drive the segment's expansion.
Uterine Fibroid Treatment Device Mode of Treatment Insights
The Uterine Fibroid Treatment Device Market segmentation, based on Mode of Treatment, includes Invasive Treatment, Minimally Invasive Treatment, and Non-invasive Treatment. This is explained by the rise in uterine fibroids incidences and symptoms in females all over the world. Due to their low cost and general acceptance, abdominal myomectomy and hysterectomy are the two most effective treatments for uterine fibroids. Therefore, it is projected that during the projection period, these factors would enhance demand for uterine fibroids treatment devices.
Figure 1: Uterine Fibroid Treatment Device Market, by Mode of Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Uterine Fibroid Treatment Device Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Uterine Fibroid Treatment Device Market dominated this market in 2022 (45.80%). This is explained by the region's existence of reputable medical institutions, growing government initiatives, and an increase in hysterectomy-related surgeries and hospital admissions.
Additionally, the availability of cutting-edge goods and the presence of significant important players like Medtronic, Stryker, and CooperSurgical, Inc. are fostering market expansion in the area. Additionally, the availability of strong distribution channels and the ease of access to healthcare technology are encouraging the use of uterine fibroids treatment equipment in the area. Further, the U.S. Uterine Fibroid Treatment Device market held the largest market share, and the Canada Uterine Fibroid Treatment Device market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Uterine Fibroid Treatment Device Market SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Uterine Fibroid Treatment Device market accounts for the second-largest market share. Due to its sophisticated healthcare system and rising knowledge of minimally invasive treatment options, Europe is predicted to have a sizable market for uterine fibroid treatment devices. The United Kingdom, France, and Germany are projected to make significant contributions to the market's expansion. The market in this area is projected to expand due to the desire for non-surgical and minimally invasive treatment alternatives including MRI-guided focused ultrasound (MRgFUS) and uterine artery embolization. Further, the German Uterine Fibroid Treatment Device market held the largest market share, and the UK Uterine Fibroid Treatment Device market was the fastest growing market in the European region
The Asia-Pacific Uterine Fibroid Treatment Device Market is expected to grow at the fastest CAGR from 2023 to 2032. This is because there are many people and more people are conscious of their health needs, which creates a sizable market opportunity for uterine fibroid treatment devices. Because uterine fibroids are becoming more common and because healthcare costs are rising, nations like China, India, and Japan are anticipated to lead market expansion. However, considerations including regulatory difficulties and disparities in the region's nations' healthcare infrastructure could have an impact on market expansion. Moreover, China’s Uterine Fibroid Treatment Device market held the largest market share, and the Indian Uterine Fibroid Treatment Device market was the fastest growing market in the Asia-Pacific region.
Uterine Fibroid Treatment Device Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Uterine Fibroid Treatment Device market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Uterine Fibroid Treatment Device industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Uterine Fibroid Treatment Device industry to benefit clients and increase the market sector. In recent years, the Uterine Fibroid Treatment Device industry has offered some of the most significant advantages to medicine. Major players in the Uterine Fibroid Treatment Device market, including Medtronic; Stryker Corporation; CooperSurgical Inc.; Ethicon, Inc.; Hologic, Inc.; Minerva Surgical, Inc.; Lumenis; Boston scientific; INSIGHTEC; Karl Storz GmbH, and others, are attempting to increase market demand by investing in research and development operations.
A medical technology firm called Medtronic Plc (Medtronic), originally known as Medtronic Inc., creates, develops, produces, and sells medical products. It provides products for the treatment of conditions such heart valve issues, heart failure, aortic, peripheral vascular, venous renal, and neurological problems, as well as spine and musculoskeletal issues, ear, nose, and throat conditions. Additionally, it offers biologic solutions for the dental and orthopedic markets. In Asia Pacific, Europe, the Americas, the Middle East, and Africa, it provides its products to hospitals, third-party healthcare providers, clinics, institutions, including governmental healthcare programs, distributors, and group purchasing groups. The headquarters of Medtronic are in Dublin, Ireland.
Stryker Corp (Stryker), a pioneer in medical technology, is a manufacturer of a range of orthopedic, medical, surgical, neurotechnology, and spine apparatus as well as associated services. Orthopedic implants, surgical tools and navigation systems, patient handling equipment, disposable intensive care supplies, and endoscopic and communication systems are among the company's primary products. Additionally, it provides spinal devices, neurosurgical equipment, and medical equipment for use in a variety of illnesses. Stryker sells items to physicians, hospitals, and other medical facilities. The corporation distributes its goods through subsidiaries, branches, independent dealers, and distributors in the Americas, Europe, Asia-Pacific, the Middle East, and Africa. Stryker's corporate office is located in Kalamazoo, Michigan, a city in the US.
Key Companies in the Uterine Fibroid Treatment Device Market Include
-
-
Stryker Corporation
-
CooperSurgical Inc
-
Ethicon, Inc.
-
-
Minerva Surgical, Inc.
-
Lumenis
-
Boston scientific
-
INSIGHTEC
-
Karl Storz GmbH
Uterine Fibroid Treatment Device Industry Developments
In March 2020, Tele Pack+ is a portable endoscopic system that Karl Storz has introduced. It is a portable video system that combines all of the essential elements—such as the camera control unit, light source, and display—needed for data management, diagnosis, and therapy.
In 2021, The MyoSure® line of devices from Hologic, Inc. have been given the go-ahead by the American Food and Drug Administration (FDA) for the removal of intrauterine tissue, including uterine fibroids. The MyoSure product line consists of three different treatments for uterine fibroids: MyoSure REACH, MyoSure XL, and MyoSure LITE..
In 2021, The debut of the EmprintTM Ablation System with ThermosphereTM Technology was announced by Medtronic Plc. This technology is made to give doctors more control and accuracy when performing the treatment to remove uterine fibroids using radiofrequency energy.
In 2020, The THUNDERBEAT Front-actuated Grip (FLEX) Surgical Tissue Management System was introduced by Olympus Corporation. This technology is made to give surgeons more control and accuracy during uterine fibroids minimally invasive operations.
In 2020, Launch of the TRUCLEAR 5C Hysteroscope and Resectoscope System was announced by Smith & Nephew plc. During hysteroscopic operations for uterine fibroids, this technology is intended to give doctors more visibility and control.
Uterine Fibroid Treatment Device Market Segmentation
Uterine Fibroid Treatment Device Technology Outlook
-
Surgical Techniques
-
Laparoscopic Techniques
-
Ablation Techniques
-
Embolization Techniques
Uterine Fibroid Treatment Device Mode of Treatment Outlook
-
Invasive Treatment
-
Minimally Invasive Treatment
-
Non-invasive Treatment
Uterine Fibroid Treatment Device Regional Outlook
-
North America
-
-
U.S.
-
Canada
-
-
Europe
-
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Rest of Europe
-
-
Asia-Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Australia
-
Rest of Asia-Pacific
-
-
Rest of the World
-
Middle East
-
Africa
-
Latin America
-
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
